- QIAGEN debuts new QIAseq panels for comprehensive genomic profiling at AACR 2025.
- Partnerships with Element Biosciences and Myriad Genetics enhance cancer research solutions.
- Free version of Human Somatic Mutation Database available for global research community.
QIAGEN N.V. (QGEN, Financial) has announced significant advancements in cancer genomic profiling through the launch of new products and updates to key partnerships at the American Association for Cancer Research (AACR) Annual Meeting 2025. These initiatives aim to bolster QIAGEN's offerings in research and clinical applications.
The new QIAseq panels have been enhanced to analyze over 700 genes, providing comprehensive genomic profiling capabilities pivotal for cancer biology research and biomarker discovery. This development represents a substantial improvement in the workflow from sample technologies to data analysis using QIAGEN Digital Insights.
Additionally, the new QIAcuity digital PCR kit and related assays are designed to support quality control in cell and gene therapy. These tools are essential for ensuring the safety and efficacy of lentivirus-based biotherapeutics, which play a crucial role in novel cancer treatments like CAR-T therapies.
As part of its ongoing collaborations, QIAGEN is integrating its QIAseq xHYB CGP Panels with Element Biosciences' AVITI platform and Trinity workflow. This integration, expected to be completed by late 2025, aims to streamline the cancer genomic profiling process, making it more efficient and cost-effective.
Moreover, QIAGEN plans to launch a sequencing-based homologous recombination deficiency (HRD) assay through its partnership with Myriad Genetics. This assay will provide deeper molecular insights into DNA repair deficiencies, aiding researchers in optimizing cancer treatment strategies.
Further supporting the research community, QIAGEN has introduced a free, limited version of the Human Somatic Mutation Database (HSMD). This database offers crucial genomic data on 25 key genes associated with solid tumors and blood cancers, expanding access to important research insights.
To discover more about QIAGEN's latest innovations, attendees can visit booth #2620 at the AACR Annual Meeting 2025. Additional details on presentations and product demonstrations can be found on QIAGEN's official website.
